Immudyne Retires 1.136 Million Shares - Planning Additional Purchases

Florence, Kentucky. September 29, 2011. Immudyne, Inc. (Pink Sheets: IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, is pleased to announce the retirement of 1,136,842 shares of the Company’s common stock purchased in a recent private transaction. Mark McLaughlin, CEO of Immudyne stated, “The retiring of these shares is part of ongoing efforts to enhance the value of our long-term shareholders’ ownership in Immudyne. With only 24.5 million shares currently outstanding, and virtually no company debt, our capital structure accommodates future growth both organically and through strategic opportunities.”

2011-09-21 14:01

Immudyne Taps Industry Veteran As Director Of Product Development

Florence, Kentucky, September 21, 2011. Immudyne, Inc. (Pink Sheets: IMMD) the world's leading research and production firm specializing in immune system support compounds based on Beta Glucan derived from baker's yeast, announced today that it has appointed Jim Roufs as Director of Product Development. Mr. Roufs brings more than twenty years of industry experience in the dietary supplement field to augment Immudyne's research and production team. He previously led New Product Development for more than seven years for the world's largest dietary supplement brand, where he participated in developing and launching numerous products with multimillion dollar annual revenues. Mr. Roufs activities will be focused on food and beverage applications for Immudyne's premier Beta Glucan product, as well as dietary supplements for immune system support and athlete training aids.

ImmuDyne Share

UltraPure Beta Glucan: clinically-effective, safe, extremely stable

Company history

ImmuDyne Inc. was founded in 1987 and pioneered research and manufacturing of Beta Glucan. The company is publicly traded (OTC: IMMD) and has offices in the US and Europe with a staff of 34 employees and advisors with a combined experience of over 70 years in applied science of Beta Glucan research and development dedicated to support the innate immune system.

Over ten years track-record in producing stable high grade Beta Glucan with a consistent production process. The company also uses proprietary processes for the production of UltraPure YBG®. ImmuDyne´s Beta Glucan has a sustainable biological activity proven over more than 10 years.

The production plant in Kentucky is fully GMP compliant and another GMP plant is under construction. The company can rely on a highly trained and experienced staff in order to produce consitently high grade, particulate and reliable Beta Glucan in a best-in-class manufacturing processes.

ImmuDyne was the first company to develop and market beta 1,3/1,6-D glucan-Macroforce® The company`s core competences lie in the research, development and manufacturing of high quality UltraPure Beta Glucan (YBG®).

Latest News

Immudyne Retires 1.136 Million Shares - Planning Additional Purchases

Immudyne Taps Industry Veteran As Director Of Product Development

Newsletter

Top Links

ImmuDyne Share

Company history